Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microencapsulated ragweed pollen extract
- Development stage
- Unknown
- Lead developer
- Curalogic
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Microencapsulated ragweed pollen extract (MRPE) is an oral allergen immunotherapy (OIT) developed by Curalogic A/S for the treatment of seasonal allergic rhinitis caused by short ragweed (*Ambrosia artemisiifolia*). The product utilizes a specialized microencapsulation technology where the pollen extract is contained within acid-resistant beads inside a capsule. This design protects the allergen from degradation by gastric acid and ensures targeted delivery to the Peyer's patches in the small intestine (duodenum and jejunum), where immunological processing occurs. By presenting the allergen to the gut-associated lymphoid tissue (GALT), MRPE aims to induce systemic immune tolerance, characterized by the modulation of allergen-specific IgE and the induction of protective IgG4 antibodies. Although it reached Phase 3 clinical trials, development was discontinued following the financial dissolution of Curalogic A/S.
- Other names
- short ragweed pollen extractmicroencapsulated short ragweed pollen extractCuralogic ragweed extract
02
Targets
Ragweed allergen-specific immunoglobulin EIgE (Immunoglobulin E)
Beyond the preview
Go deeper on microencapsulated ragweed pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microencapsulated ragweed pollen extract.